CD19 CAR-T Cell Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase I/II Study

Study acronym: CARLLA-B1
StatusNot Yet Recruiting
PhasePhase 1/2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This is a Phase I/II study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 in adult patients with relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (ALL).
Trial Details
NCT Number NCT07890025
Lead Sponsor Hospital Universitario Dr. Jose E. Gonzalez
Conditions
(from sponsor)		 Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
Related terms Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Recurrence
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov